347 related articles for article (PubMed ID: 35544585)
1. COVID-19 in patients with hematologic malignancy.
Langerbeins P; Hallek M
Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
[TBL] [Abstract][Full Text] [Related]
2. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Guo W; Zheng Y; Feng S
Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
[TBL] [Abstract][Full Text] [Related]
3. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.
El Chaer F; Auletta JJ; Chemaly RF
Blood; 2022 Aug; 140(7):673-684. PubMed ID: 35776899
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.
Wang L; Wang W; Xu R; Berger NA
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101384. PubMed ID: 36494154
[TBL] [Abstract][Full Text] [Related]
5. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
6. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
8. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
Pagano L; Salmanton-García J; Marchesi F; Blennow O; Gomes da Silva M; Glenthøj A; van Doesum J; Bilgin YM; López-García A; Itri F; Nunes Rodrigues R; Weinbergerová B; Farina F; Dragonetti G; Berg Venemyr C; van Praet J; Jaksic O; Valković T; Falces-Romero I; Martín-Pérez S; Jiménez M; Dávila-Valls J; Schönlein M; Ammatuna E; Meers S; Delia M; Stojanoski Z; Nordlander A; Lahmer T; Imre Pinczés L; Buquicchio C; Piukovics K; Ormazabal-Vélez I; Fracchiolla N; Samarkos M; Méndez GA; Hernández-Rivas JÁ; Espigado I; Cernan M; Petzer V; Lamure S; di Blasi R; Marques de Almedia J; Dargenio M; Biernat MM; Sciumè M; de Ramón C; de Jonge N; Batinić J; Aujayeb A; Marchetti M; Fouquet G; Fernández N; Zambrotta G; Sacchi MV; Guidetti A; Demirkan F; Prezioso L; Ráčil Z; Nucci M; Mladenović M; Liévin R; Hanáková M; Gräfe S; Sili U; Machado M; Cattaneo C; Adžić-Vukičević T; Verga L; Labrador J; Rahimli L; Bonanni M; Passamonti F; Pagliuca A; Corradini P; Hoenigl M; Koehler P; Busca A; Cornely OA
Blood; 2022 Dec; 140(26):2773-2787. PubMed ID: 36126318
[TBL] [Abstract][Full Text] [Related]
10. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
Laracy JC; Yan J; Steiger SN; Tan CA; Cohen N; Robilotti EV; Fender J; Cohen S; Korde N; Lee-Teh M; Noy A; Oved JH; Roeker LE; Shah G; Babady NE; Kamboj M; Seo SK
Haematologica; 2023 Nov; 108(11):3058-3067. PubMed ID: 37345467
[TBL] [Abstract][Full Text] [Related]
11. Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.
Shaw B; Shortt J; Low M; Rogers B; Kaplan Z; Fedele P; Gregory G; Vilcassim S; Gilbertson M; Grigoriadis G; Opat S
Intern Med J; 2022 Dec; 52(12):2172-2175. PubMed ID: 36436197
[TBL] [Abstract][Full Text] [Related]
12. Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations.
Passamonti F; Nicastri E; Di Rocco A; Guarini A; Ibatici A; Luminari S; Mikulska M; Visco C
Hematol Oncol; 2023 Feb; 41(1):3-15. PubMed ID: 36251481
[TBL] [Abstract][Full Text] [Related]
13. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy.
Giesen N; Sprute R; Rüthrich M; Khodamoradi Y; Mellinghoff SC; Beutel G; Lueck C; Koldehoff M; Hentrich M; Sandherr M; von Bergwelt-Baildon M; Wolf HH; Hirsch HH; Wörmann B; Cornely OA; Köhler P; Schalk E; von Lilienfeld-Toal M;
Eur J Cancer; 2021 Apr; 147():154-160. PubMed ID: 33676266
[TBL] [Abstract][Full Text] [Related]
14. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
[TBL] [Abstract][Full Text] [Related]
15. Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study.
Rooney A; Bivona C; Liu B; Streeter D; Gong H; Khan Q
J Hematol Oncol; 2022 May; 15(1):67. PubMed ID: 35597960
[TBL] [Abstract][Full Text] [Related]
16. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
17. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.
Teh JSK; Coussement J; Neoh ZCF; Spelman T; Lazarakis S; Slavin MA; Teh BW
Blood Adv; 2022 Apr; 6(7):2014-2034. PubMed ID: 34852173
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
